Clinicians should avoid using unapproved pain medications in intrathecal and intraspinal drug delivery systems, the FDA announced in an alert on Nov. 15.
After a thorough review of the literature, along with information from health care professionals and device companies, the FDA has become aware that some physicians are choosing unapproved medications in these pumps, most commonly to avoid unwanted side effects of approved drugs or provide stronger pain relief, the agency said. Using unapproved